Top-line Phase 3 Data: Extended-release Oral Minoxidil Demonstrates “Early, Sustained, and Robust” Hair Growth in Male-pattern Hair Loss

VDPHL01, Veradermics’ extended-release oral minoxidil formulation, hit all primary and secondary endpoints in both active treatment arms, according to positive topline results from Part A of its randomized, double-blind, placebo-controlled registration-directed Phase 3 clinical trial (Study ‘304’).